INTIInhibitor Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Inhibitor Therapeutics, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INTIEsta | — | — | — | — | — | 1.2%#4 | — | — | — | — | — | — |
| IMRN | $278M#4 | — | — | — | — | — | — | — | — | — | -34.6%#4 | — |
| IMRX | — | — | — | — | -100.0%#7 | 8.2%#3 | — | -29.4%#3 | — | — | -50.7%#5 | — |
| INBP | — | — | — | — | 8.0%#2 | 621.4%#2 | 3.7%#2 | 4.3%#1 | 6.0%#2 | 7#1 | — | — |
| INCR | $312M#3 | — | — | — | — | — | — | — | — | — | -26.8%#2 | — |
| INDV | $4.1B#1 | 12.5x#3 | — | 3.3x#1 | 4.3%#3 | 2900.0%#1 | 21.1%#1 | — | 403.9%#1 | 4#2 | 52.4%#1 | — |
| IOBTQ | — | — | — | — | — | -10.9%#5 | — | -10483.0%#5 | — | — | — | — |
| ISCO | — | — | — | — | 0.2%#4 | -100.0%#7 | -2.9%#3 | — | — | — | — | — |
| IVA | $722M#2 | — | — | — | — | — | — | — | — | — | -33.1%#3 | — |
| IXHL | $44M#5 | 0.2x#2 | 0.6x#1 | 513.4x#2 | 616.7%#1 | -154.0%#8 | -27661.6%#5 | -62.3%#4 | -521.0%#4 | — | -77.1%#6 | — |
| JAGX | — | 0.0x#1 | — | — | -1.5%#5 | -37.6%#6 | -398.8%#4 | -0.3%#2 | -160.9%#3 | — | -99.7%#7 | — |
| KAYS | — | — | — | — | -96.4%#6 | -229.3%#9 | -28343.5%#6 | — | -846.8%#5 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice